Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending April 29, 2018
Public's conflicts of interest often are undeclared at FDA advisory meetings , McCoy MS et al. JAMA Intern Med. 2018 Apr 23
Must reads for theWeek ending April 22, 2018
Atovaquone associated with increased nocardiosis risk, Molina A et al. Acute Leukemia Forum 2018, Poster Session.
Add-on ibrutinib boosted response in relapsed multiple myeloma, Chari A et al. Leuk Lymphoma. 2018 Apr 4. doi: 10.1080/10428194.2018.1443337.
Adding statin boosted AML response rate, Advani AS et al. Leuk Res. 2018 Apr;67:17-20.
Venetoclax is effective in CLL that relapses after idelalisib, , Coutre S et al. Blood. 2018;131(15):1704-11
Pembrolizumab after cytarabine boosts AML response, Zeidner J et al. Acute Leukemia Forum 2018, Poster Session.
Must reads for theWeek ending April 22, 2018
Atovaquone associated with increased nocardiosis risk, Molina A et al. Acute Leukemia Forum 2018, Poster Session.
Add-on ibrutinib boosted response in relapsed multiple myeloma, Chari A et al. Leuk Lymphoma. 2018 Apr 4. doi: 10.1080/10428194.2018.1443337.
Adding statin boosted AML response rate, Advani AS et al. Leuk Res. 2018 Apr;67:17-20.
Venetoclax is effective in CLL that relapses after idelalisib, , Coutre S et al. Blood. 2018;131(15):1704-11
Pembrolizumab after cytarabine boosts AML response, Zeidner J et al. Acute Leukemia Forum 2018, Poster Session.
Must reads for theWeek ending April 15, 2018
FDA issues draft guidance on pregnant women in clinical trials, Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials; Draft Guidance. FDA April 9, 2018
Impact of industry payment on prescribing practices , Mitchell AP et al. JAMA Intern Med. 2018 Apr 9. doi: 0.1001/jamainternmed.2018.0776.
Physician attitudes about Medicaid work requirements , Merritt Hawkins survey, March 2018
Little awareness of U.S. cancer drug shortages, Frosch ZAK et al. Cancer. 2018 Apr 8. doi: 10.1002/cncr.31246
Health IT: Few practices are taking full advantage, Rumball-Smith J et al. Am J Manag Care. 2018;24(1):26-31
Must reads for theWeek ending April 8, 2018
Partial nephrectomy is even more critical in early-onset RCC, Clemmensen T et al. Human Pathology April 2018 25-31. https://doi.org/10.1016/j.humpath.2017.11.005
PD-L1 status and aggressive clear cell RCC, Lopez J et al. Annals of Diagnostic Pathology June 2018, Pages 89-93 https://doi.org/10.1016/j.anndiagpath.2018.03.007
BAP1, PBRM1, and metabolic pathway changes correlate with RCC subtype-specific survival, Ricketts C et al. Cell Reports April 2018, Pages 313–326.e5 https://doi.org/10.1016/j.celrep.2018.03.075
RCCs more than 50% cystic have good prognosis, Kashan M et al. The Journal of Urology 1 March 2018 https://doi.org/10.1016/j.juro.2018.02.3087
Stereotactic radiosurgery yields higher overall survival in patients with RCC metastatic to the brain, Haque W et al. Clinical Genitourinary Cancer 3 April 2018 https://doi.org/10.1016/j.clgc.2018.03.015